• No results found

anti-PD-L1

Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials

Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials

... of anti-PD-1/anti-PD-L1 agents (atezolizumab, nivolumab and pembrolizumab) was associated with better OS in comparison with docetaxel alone (HR: ...any ...

11

Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy

Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy

... an anti-mouse PD-L1 antibody ...the PD-L1 inhibitor in various animal studies, as a positive control ...the PD-L1 antibody showed a slower tumor growth ...human ...

14

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma

... as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) monoclonal antibodies including ipilimumab; anti-PD-1 monoclonal antibodies including nivolumab and pembrolizumab; ...

7

Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer

Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer

... induce PD-L1 expression and CD8 recruit- ment at tumour ...an anti-PD-L1 in combination with standard treatment of CRC (oxaliplatin, fluoro- uracil and leucovorin (FOLFOX)), while ...

9

Irradiation and anti–PD L1 treatment synergistically promote antitumor immunity in mice

Irradiation and anti–PD L1 treatment synergistically promote antitumor immunity in mice

... when PD-L1 is expressed in chronically inflamed tissues and ...that PD-L1 was upregulated in the tumor microenvironment after ...of antiPD-L1 enhanced the efficacy of IR ...

10

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination

... with anti-TIGIT and anti-PD-L1 ...of PD-L1 in a sustainable manner, but significantly decreased the ex- pression of ...of PD-L1 and ...studied anti-TIGIT ...

12

Enhanced killing of chordoma cells by antibody-dependent cell- mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab

Enhanced killing of chordoma cells by antibody-dependent cell- mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab

... of PD-L1 expression in chordoma (Figure 1) suggested potential clinical benefit from PD-1/ PD-L1 pathway ...Several anti-PD-L1 antibodies have been generated and ...

14

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

... Paraneoplastic syndromes (PNSs) are rare autoimmune disorders associated with cancer [7, 8]. The complex pathogenesis of these syndromes is mediated by either sol- uble factors (such as hormones or cytokines secreted by ...

12

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

... manufacturer’s instruction (BD Biosciences, San Jose, CA). Briefly, 50 μl of blood from hHSC-transplanted mice (day 18, pre-treatment; day 34, after three treat- ment doses; day 46, after four treatment doses), was added ...

14

Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy

Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy

... broader anti-tumor efficacy as compared to either ...of PD-1 treatment-resist- ant metastatic NSCLC patients achieved disease control, with 27% partial responses and 64% stable disease after concurrent ...

16

Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma

Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma

... ligand PD-L1, expressed on antigen presenting cells and tumor cells (TCs) ...[9]. Anti-PD-1 or anti-PD-L1 antibodies have clinically benefitted patients with some solid ...

13

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

... of antiPD-1 or antiPD-L1 therapy in cancer patients who were seropositive for ...of antiPD-1 or antiPD- L1 therapy; (3) had been tested for ...

10

Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors

Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors

... with anti-PD-L1 ...of PD-L1 in the immune system, it is consistent that PD-L1 is expressed on AMs to converge immune ...addition, PD-L1 staining intensity of ...

8

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

... community. PD-L1, typically expressed on the surface of healthy cells, binds PD-1 on primed cytotoxic T cells thereby inhibiting cell-mediated attack ...ing PD-L1 [2, ...potential. ...

6

Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma

Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma

... of PD-L1 in primary ESCC were associated with a poor clinical ...of PD-L2. PD-L2 seems to be expressed in a higher proportion of tumors ...than PD-L1 (53.9%), and PD-L2 ...

12

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

... of PD-L1 IHC for predicting response to immune checkpoint ...of PD-L1 by IHC is generally associated with a higher proportion of objective response, [72] patients without expression of ...

16

Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade

Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade

... of PD-1/PD-L1 blockade on immune cell function, PBMC from BLV-infected cat- tle were cultivated in the presence of ConA together with either an anti-PD-L1 or an isotype control ...

15

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond

... to PD-L1 blockade required specific Bacter- oides - mice which were given oral Bifidobacterium improved tumor control to the same degree as those given an anti-PD-L1 agent ...

10

Expression of PD L1 in triple negative breast cancer based on different immunohistochemical antibodies

Expression of PD L1 in triple negative breast cancer based on different immunohistochemical antibodies

... for PD-L1 in PD-L1-expressing can- cers represents a possible treatment for inducing anti- tumor immune ...responses. PD-L1-targeted therapy has been investigated in ...

12

Targeting PD-1/PD-L1 in lung cancer: current perspectives

Targeting PD-1/PD-L1 in lung cancer: current perspectives

... of nivolumab every 2 weeks. This trial included patients regardless of their PD-L1 status. The most common adverse reactions (reported in $20% of patients) were fatigue (50%), dyspnea (38%), musculoskeletal ...

16

Show all 10000 documents...

Related subjects